Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지

Long Term Follow Up Results of Serum Squamous Cell Carcinoma Antigen Level in Uterine Cervix Cancer Treated by Radiotherapy

자궁경부암 방사선치료 후 혈중 Squamous Cell Carcinoma 항원치의 장기추적 결과

  • Yun, Hyong-Geun (Department of Radiation Oncology, Dankook University College of Medicine)
  • 윤형근 (단국대학교 의과대학 방사선종양학교실)
  • Published : 2003.12.01
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To evaluate the long term significance of the squamous cell carcinoma (SCC) antigen (Ag) as a tumor marker in uterine cervix carcinoma. Materials and Methods: The SCC antigen levels of pre-radiotherapy and serial post-radiotherapy serum were analyzed in 48 patients who received radiotherapy with histologically proven primary SCC of the uterine cervix. Results: Pre-radiotherapy SCC Ag level was high ($\geq$2 ng/ml) at 79.2$\%$. After the treatment, the SCC Ag level was significantly decreased. The SCC Ag level measured at about 3 months after radiotherapy was high at 23.0$\%$. In further follow up measurements, a rise of the SCC Ag to a high level was well associated with clinical relapse. The specificity of the elevated SCC Ag level in association with recurrent or persistent disease was 100$\%$, and the sensitivity was 85.7$\%$. In 3 of 4 lung metastasis cases, lung lesions were detected in chest PA before elevation of the SCC Ag level. The median lead time of the high SCC Ag level to clinical recurrence was 4 months. Conclusion: SCC Ag was a good tumor marker for monitoring treatment effect in patients with increased pre-treatment levels except in case of early lung metastasis. Elevation of the SCC Ag level after radiotherapy accurately predicted the treatment failure with lead time of 4 months. But, in early lung metastasis cases, the SCC level may be normal temporarily. Thus, chest PA should be checked to evaluate the presence of lung metastasis.

목적: 자궁경부암의 방사선치료 후의 재발이나 병소의 지속을 발견하기 위한 종양표지자로서의 Squamous cell carcinoma (SCC) 항원의 의의를 장기간의 경과관찰을 통해서 확인하고자 하였다. 대상 및 방법: 1995년 10월부터 2001년 5월까지 단국대학병원 방사선종양학과에서 원발성 자궁경부암으로 근치적 방사선치료를 시행 받은 환자 중 치료 전후에 혈중 SCC 항원치를 주기적으로 측정한 48예를 대상으로 하였다. 결과: 방사선치료 전에 측정한 SCC 항원치는 전체의 79.2$\%$에서 정상치 보다 높았다. 치료 후에 SCC 항원치는 유의하게 감소하였으며 치료 후 3개월 경에는 23.0$\%$에서 정상치 보다 높았다. 병소의 완전 관해가 이루어지고 치료실패가 일어나지 않은 경우는 6개월 이후의 장기적인 관찰 중 SCC 항원치는 결국 정상범위가 되었다. 치료 후의 장기적인 경과 관찰 중에 SCC 항원치가 재상승하여 지속적으로 높은 값을 나타낸 경우는 치료실패를 아주 잘 예측하였으며 SCC 항원치의 재상승과 임상적 치료실패 확인 사이의 시간간격(lead time)의 평균은 4개월이었다 재발과 관련된 SCC 항원치의 지속적 상승의 민감도는 85.7$\%$, 특이도는 100.0$\%$이었다. 첫 번째 치료실패가 폐 전이로 나타났던 4예 중 3예에서는 SCC 항원치의 재상승이 일어나기 전에 흉부단순 촬영 소견에서 폐 전이가 나타났으나 그 외의 모든 임상적 재발 시에는 SCC 항원치의 재상승이 동반되거나 선행되었다. 결론: 본 연구에서 치료 전 SCC 항원치가 높았던 경우에 치료 후 SCC 항원치의 지속적 상승은 치료 실패를 정확하게 예견하게 해 주는 좋은 예후인자였으며 SCC 항원치 상승과 치료실패 사이의 시간간격은 평균 4개월이었다. 그러나 치료 전 SCC 항원치가 높은 경우의 치료실패 양상 중, 폐 전이 초기와 같이 종양부피가 작은 경우는 처음에는 일시적으로 SCC항원치가 정상범위로 관찰될 수 있으므로 경과 관찰 시 반드시 흉부단순 촬영을 병행하여 폐 전이 여부를 함께 관찰하여야 할 것으로 생각된다.

Keywords

References

  1. KatoH,TorigoeT. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer 1977; 41:621-1628
  2. Maruo T, Yoshida S, Samoto T, et al. Factors regulating SCC antigen expression. The 20th Anniversary Workshop on SquamousCell Carcinoma Antigen, Fukuoka, Japan 1997
  3. Maruo T, Yamasaki M, Ladines-Llave, et al. Immunohistochemical demonstration of elevated expression of epidermal growth factor receptor in the neoplastic changes of cervical squamous epithelium. Cancer 1992;69:1182-1187 https://doi.org/10.1002/cncr.2820690519
  4. Hussa RO, Maruo T, Strobel, et al. Production of tumor associated antigen, TA-4, by the Caskicervicalcarcinoma cell line.Obstet Gynecol 1986;67:802-805 https://doi.org/10.1097/00006250-198606000-00010
  5. YunHG,ParkSK . Serial Determinations of SerumSquamous Cell Carcinoma Antigen (SCC) during Radiotherapy for Uterine Cervix. J Kor Societ Radiat Oncol 2001; 19(2):136-141
  6. Yun HG, Park CH. Pre-radiotherapy and Post-radiotherapy SerialSerum Squamous Cell Carcinoma Antigen (SCC) and Carcinoembryonic Antigen (CEA) in the Monitoring of Squamous Cell Carcinoma of UterineCervix.J Kor Societ Radiat Oncol 1999;17(1):30-35
  7. Ohara K, Tanaka Y, Tsunoda H, Nishida M, Sugahara S, Itai Y. Assessment of cervical cancer radioresponse by serum squamous cellcarcinomaantigen and magnetic resonance imaging. Obstet Gynecol 2002;100(4):781-787 https://doi.org/10.1016/S0029-7844(02)02204-4
  8. Takeda M, Sakuragi N, Okamoto K. Preoperative serum SCC, CA125, and CA19-9 levels and lymph node status in squamous cell carcinoma of the uterine cervix. Acta Obstet Gynecol Scand 2002;81(5):451-457 https://doi.org/10.1034/j.1600-0412.2002.810513.x
  9. Gaarenstroom KN, Kenter GG, Bonfrer JM, et al. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamouscellcervical cancer predict lymphnodemetastases or prognosis? Gynecol Oncol 2000;77(1):164-170
  10. LinH,ChangChienCC,HuangEY,Tseng CW, EngHL,HuangCC The role of pretreatment squamouscellcarcinomaantigen in predicting nodal metastasis in early stage cervical cancer. Acta Obstet Gynecol Scand 2000; 79(2):140-144
  11. Ngan HY, Cheng GT, Wong LC, et al. Post-treatment serial serum squamous cell carcinoma antigen (SCC) in the monitoring of squamouscellcarcinoma of the cervix. Int J Gynecol Cancer 1996;6:115-119 https://doi.org/10.1046/j.1525-1438.1996.06020115.x
  12. DukJM,deBruijnHW,GroenierKH,etal. Cancer of the uterine cervix: sensitivity and specifity of serum squamous cell carcinoma antigen determinations. Gynecol Oncol 1990;39:186-194 https://doi.org/10.1016/0090-8258(90)90430-S
  13. Holloway RW, To A , M o r a M , e t a l . Monitoring the course of cervical carcinoma with the squamous cell carcinoma serum radioimmunoassay.ObstetGynecol 1989;79:944-949
  14. Rose PG, Baker S, Fournier L, et al. Serum squamous cell carcinoma antigen levels in invasive cervical cancer: prediction of response and recurrence. Am J Obstet Gynecol 1993;168:942-946 https://doi.org/10.1016/S0002-9378(12)90850-9
  15. Senekjian EK, Young JM, Weiser PA, et al. An evaluation of squamous cellcarcinoma antigen inpatientswith cervical squamous cell carcinoma. Am J Obstet Gynecol 1987;157:433-439 https://doi.org/10.1016/S0002-9378(87)80187-4
  16. MaruoT,ShibataK,KimuraA,etal. Tumor-associated antigen, TA-4, in the monitoring of therapy for squamous cell carcinoma of the uterinecervix:Serial determination and tissue localization. Cancer 1985;56:302-308 https://doi.org/10.1002/1097-0142(19850715)56:2<302::AID-CNCR2820560217>3.0.CO;2-T
  17. Ngan HY, Cheng GT, Wong LC, et al. Serum squamous cell carcinoma antigen in the monitoring of radiotherapy treatment response in carcinoma of the cervix. Gynecol Oncol 1990;37:260-263 https://doi.org/10.1016/0090-8258(90)90344-K
  18. KatoH,MoriokaH,ArakamiS,etal. Prognostic significance of thetumorantigenTA-4insquamouscellcarcinoma of the uterine cervix. Am J Obstet Gynecol 1983; 145:350-354 https://doi.org/10.1016/0002-9378(83)90723-8
  19. OhnoT,NakayamaY,NakamotoS,etal. Measurementofserum squamouscellcarcinomaantigen levels as a predictor of radiation response in patients with carcinoma of the uterine cervix. Cancer 2003;97(12):3114-3120 https://doi.org/10.1002/cncr.11453
  20. MickeO,ProttFJ,SchaferU,et al. The impact of squamous cell carcinoma (SCC) antigen in the follow-up after radiotherapy in patients with cervical cancer. Anticancer Res 2000;20(6D):5113-5115
  21. YuanCC,WangPH,NgHT,Tsai LC, Juang CM,ChiuLM. Both TPA andSCC-Ag levels are prognostic even in high-risk stage Ib-IIa cervical carcinoma as determined by a stratification analysis. Eur J Gynaecol Oncol 2002;23(1): 17-20
  22. Pras E,WillemsePH,CanrinusAA, et al. Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment. IntJRadiatOncolBiolPhys2002;52(1): 23-32
  23. Chan YM, Ng TY, Ngan HY, Wong LC. Monitoring of serum squamous cell carcinoma antigen levels in invasive cervical cancer: is it cost-effective? Gynecol Oncol 2002; 84(1):7-11
  24. EsajasMD,DukJM,DeBruijnHW,etal. Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer. J Clin Oncol 2001;19:3960-3966 https://doi.org/10.1200/JCO.2001.19.19.3960
  25. CopurS,LedakisP,NovinskiD,etal. Squamous cellcarcinoma of the colon with an elevated serum squamous cell carcinoma antigen responding to combination chemotherapy. Clin Colorectal Cancer 2001;1(1):55-58 https://doi.org/10.3816/CCC.2001.n.006
  26. Tabata T,Takeshima N, Tanaka N, Hirai Y, Hasumi K. Clinical valueoftumormarkers for earlydetectionofrecurrence in patients with cervical adenocarcinoma and adenosquamous carcinoma. Tumour Biol 2000;21(6):375- 380 https://doi.org/10.1159/000030143